The Board of Directors of the Company have approved the unaudited Financial Results for the Quarter ended June 30th 2025 at their meeting held on July 23, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs reported its Q1 FY26 results (quarter ended June 30, 2025), approved by the Board on July 23, 2025. Revenue from operations jumped sharply to Rs. 121.03 lakhs from Rs. 10.40 lakhs in the same quarter last year, a more than 10-fold increase. However, other income fell to zero (vs Rs. 102.32 lakhs last year), pulling total revenue down to Rs. 121.03 lakhs from Rs. 135.60 lakhs. Net profit collapsed to Rs. 3.74 lakhs (EPS Rs. 0.071) from Rs. 77.82 lakhs (EPS Rs. 1.485) a year ago, mainly because last year's profit was inflated by that one-time other income. The statutory auditor PPKG & Co. issued an unmodified limited review conclusion. Total assets stood at Rs. 711.67 lakhs with negative other equity of Rs. (84.97) lakhs, indicating accumulated losses from prior years.
Core operating revenue shows very strong growth, but profitability remains thin and the bottom line is heavily reduced compared to the prior-year quarter. Negative other equity signals past accumulated losses, so shareholders should watch whether the operating growth translates into sustainable profits in coming quarters. Short-term stock reaction may be mixed given the headline profit drop.